Research Article
Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons
Table 1
Baseline characteristics of the study sample, overall and by obese status.
| | | Overall
() | Nonobese
(BMI < 30 kg/m2)
() | Obese
(BMI ≥ 30 kg/m2)
() | value |
| | Median age (IQR), year | 46 (38–52) | 46 (37–53) | 44 (38–51) | 0.56 | | Sex, (%) | | | | | | Male | 125 (71) | 102 (80) | 23 (48) | <0.001 | | Female | 51 (29) | 26 (20) | 25 (52) | | Race, (%) | | | | | | White | 54 (31) | 44 (34) | 10 (21) | 0.17 | | Black | 121 (68) | 83 (65) | 38 (79) | | Asian/Pacific-Islander | 1 (0.6) | 1 (0.8) | 0 (0) | | Diabetes, (%) | 12 (6.8) | 4 (3.1) | 8 (16.7) | 0.002 | | Chronic hepatitis B, (%) | 10 (5.7) | 10 (7.8) | 0 (0) | 0.05 | | Chronic hepatitis C, (%) | 25 (14) | 19 (15) | 6 (12) | 0.69 | | Receiving ART, (%) | 156 (87) | 114 (89) | 42 (88) | 0.77 | | PI-based | 85 (48) | 63 (49) | 22 (46) | 0.56 | | NNRTI-based | 43 (24) | 30 (23) | 13 (27) | | INSTI-based | 10 (5.7) | 8 (6.2) | 2 (4.2) | | Other | 24 (14) | 15 (12) | 9 (19) | | No ART/unknown | 14 (8.0) | 12 (9) | 2 (4.2) | | ZDV, ddI, and d4T use | 19 (11) | 14 (11) | 5 (10) | 0.92 | |
HIV RNA <400 copies/mL, (%) | 146 (83) | 105 (83) | 41 (85) | 0.66 | | Median nadir CD4 count (IQR), cells/μL | 168 (42–322) | 156 (38–304) | 197 (68–354) | 0.25 | | Median current CD4 count (IQR), cells/μL | 452 (294–640) | 438 (280–630) | 498 (406–690) | 0.09 | | Median BMI (IQR), kg/m2 | 25 (22–31) | 24 (22–26) | 36 (32–39) | <0.001 | | Receipt of HD vaccine, (%) | 91 (52) | 64 (50) | 27 (56) | 0.46 |
|
|
ART: antiretroviral therapy; BMI: body mass index; ddI: didanosine; d4T: stavudine; HD: high dose; IQR: interquartile range; INSTI: integrase strand transfer inhibitor; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor; ZDV: zidovudine.
|
